Metagenomic assessment of gut microbial communities and risk of severe COVID-19Original paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether gut microbial communities are linked to the severity of COVID-19 in hospitalized patients. Researchers profiled stool samples using metagenomic sequencing to identify gut microbial taxa, their biochemical pathways, and stool metabolites associated with disease severity. They also built a random forest classifier to test whether microbiome data could distinguish severe from moderate COVID-19, and used network analyses to examine microbial community structure.
Who was studied?
The study included 127 hospitalized patients with COVID-19, of whom 79 had severe disease and 48 had moderate disease. These patients collectively provided 241 stool samples collected from April 2020 to May 2021. The classifier's performance was also externally validated in an independent cohort, though details of that cohort are not given in the abstract.
What were the most important findings?
Forty-eight microbial species were associated with severe COVID-19 after accounting for antibiotic use, age, sex, and comorbidities. Severe disease was marked by significant in-hospital depletion of Fusicatenibacter saccharivorans and Roseburia hominis, two commensals previously linked to post-acute COVID syndrome, or long COVID, suggesting they may serve as early biomarkers for its later development. The random forest classifier achieved excellent performance distinguishing severe from moderate COVID-19 stool samples, a result that held up in external validation, and network analysis pointed to fragility in the gut microbial community structure of severe cases.
What are the greatest implications of this study?
The findings suggest that gut microbial depletion during acute COVID-19, particularly of Fusicatenibacter saccharivorans and Roseburia hominis, could help identify patients at risk of developing long COVID before it manifests. The strong, externally validated classifier performance indicates that stool-based microbiome signatures could become a practical tool for stratifying COVID-19 severity risk. These results also reinforce the broader role of specific gut commensals in shaping immune resilience during respiratory viral infection.